WHY?
-
MRD is an important prognostic factor for outcomes in Ph+ ALL1,2,5–7
WHAT?
-
Achievement of an MMR seems to be significantly prognostic for RFS7
-
Achievement of CMR at 3 months has been demonstrated to be predictive of higher long-term survival6
-
Measuring MRD early, at the end of induction therapy, can identify patients at low risk of relapse, while measuring MRD at the end of consolidation therapy identifies patients at high risk of relapse1
-
The ability to assess the potential risk of relapse using MRD helps to inform subsequent clinical decisions1